Palifosfamide Phase III Blowup
At 'Threshold,' Ziopharm's Bid in Sarcoma Fails; Refocus Due
By Randy Osborne
Wednesday, March 27, 2013
Ziopharm Oncology Inc.'s Phase III trial with the alkylating agent palifosfamide for first-line, metastatic soft tissue sarcoma failed to meet the primary endpoint of progression-free survival (PFS), but the company shifting its efforts to synthetic biology programs partnered with Intrexon Corp. will continue to follow patients' overall survival (OS) rates.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.